Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

The Motley Fool. DATE Thursday, Apr 24, 2025 Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS Daniel O'Day: Chairman and Chief ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of ...

Short interest in Gilead Sciences Inc (NASDAQ:GILD) decreased during the last reporting period, falling from 22.34M to 21.39M. This put 1.72% of the company's publicly available shares short.